Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer. (6th November 2014) - Foy, Susan P; Rountree, Ryan B; Cote, Joseph; dela Cruz, Tracy; Gordon, Evan; Trent, Erica; Franzusoff, Alex; Breitmeyer, James B; Mandl, Stefanie J